Scientific Advisory Board

The Scientific Advisory Board (SAB) for the Vascular Cures Research Network (VCRN) is a world-class Scientific Advisory Board, including leading experts in cardiovascular medicine, surgery, pathology, genetics, biochemistry, and clinical trials. The SAB determines the VCRN research priorities, and will develop the study designs and protocols for the initial project, define the requisite characteristics of the biobank and clinical database platforms, and propose and develop subprojects.


Scott Berceli, MD, PhD

Scott Berceli, MD, PhD is currently Professor of Surgery and Bioengineering at the University of Florida, and Chief of Vascular Surgery at the North Florida/South Georgia VA. He received his B.S. in Chemical Engineering from the Massachusetts Institute of Technology, followed by his M.D. and Ph.D. in Chemical Engineering from the University of Pittsburgh. Through development of a multidisciplinary team involving engineers, vascular biologists, mathematicians and clinicians, Dr. Berceli has brought a multi-scale, systems level understanding to the dynamics of vascular remodeling, with an emphasis on understanding these events in human pathology. He is a leader of the Industry/University Cooperative Research Center (I/UCRC) at University of Florida, funded by the NSF. The goal of the NSF program is to contribute to the nation’s research infrastructure base by developing long-term partnerships among industry, academia and government. Dr. Berceli is a key participant in the Vascular Cures Research Network.


Michael S. Conte, MD

Michael S. Conte, MD is the Chief Medical Officer of Vascular Cures, Professor and Chief of the Division of Vascular and Endovascular Surgery at UCSF and Co-Director of the UCSF Heart and Vascular Center. Previously, he was the Associate Professor of Surgery at Harvard Medical School and Director of Vascular Surgery Research at Brigham and Women’s Hospital, Boston. He was also Co-Director of the Clinical Trials Group at the Center for Surgery and Public Health, a joint initiative of Harvard Medical School, Brigham and Women’s Hospital, and the Harvard School of Public Health. He has authored or co-authored more than 100 peer-reviewed publications, as well as numerous book chapters and reviews. He is a Distinguished Fellow of the Society for Vascular Surgery and has served on the scientific advisory board of several biotechnology/pharmaceutical companies. He served as an Associate Editor for Circulation, and is currently on the editorial boards of the Journal of Vascular Surgery, Vascular Medicine, Vascular and Endovascular Surgery, and Vascular.


Zorina S. Galis, Ph.D.

Zorina S. Galis, Ph.D. is the Chief of Vascular Biology and Hypertension at the National Heart, Lung, and Blood Institute (NHLBI) /National Institutes of Health (NIH), overseeing a large and diverse extramural portfolio of basic, translational, and clinical research. Zorina also participates in organizing scientific conferences and servers as a reviewer for professional journals, foreign government and non-government biomedical agencies. Previously Zorina rose through the academic ranks at Harvard Medical School, and then to a tenured position in Emory School of Medicine and Georgia Institute of Technology. Subsequently, Zorina simultaneously held the positions of Chief Scientific Officer, Cardiovascular R&D at Eli Lilly and Co. and Professor of Vascular Surgery, at Indiana University. Zorina is recognized for her significant scientific contributions to the area of vascular remodeling, in relation to acute clinical syndromes, hypertension, and bioengineered grafts. She has excelled in establishing, training, and leading successful interdisciplinary teams of scientists, engineers, cardiology and surgical fellows, drug developers, and of research administrators. Zorina was trained in physics, biophysics, cell biology, pathology, and vascular medicine at the University of Bucharest, Romania, the McGill University School of Medicine, Montreal, Canada, and the Harvard School of Medicine, Boston, USA. 


John Kane, MD, PhD

John Kane, MD, PhD is the Director of the Adult Lipid Clinic at University of California at San Francisco. He earned his medical degree at the University of Oregon School of Medicine, then completed an internship and residency in internal medicine at Stanford University and the University of California, San Francisco (UCSF) and a fellowship in endocrinology at UCSF. His research in lipoprotein metabolism, the management of disorders of lipoproteins, and the genetic bases of heart disease and stroke is known worldwide through his publications in refereed journals and book chapters. Dr. Kane is Professor of Medicine and Professor of Biochemistry and Biophysics, and is an Associate Director of the Cardiovascular Research Institute at UCSF. He is a fellow of the Established Investigator of the American Heart Association. Dr. Kane is a recent recipient of an Outstanding Achievement Award in the Genetics of Lipoprotein Metabolism and Atherosclerosis from the International Atherosclerosis Society. He is a diplomate of the American Board of Clinical Lipidology.


Larry Kraiss, MD

Larry W. Kraiss, MD is Professor and Chief of the Division of Vascular Surgery at the University of Utah. He received his medical degree from Baylor College of Medicine. Dr. Kraiss' general and vascular surgical training was at the University of Washington in Seattle where he also spent three years in the vascular biology research laboratory of Dr. Alexander Clowes. He joined the faculty at the University of Utah in 1995 where he established an NIH-funded research laboratory studying translational control in endothelial cells and was named Vascular Surgery Division Chief in 2003. He is also Director of the vascular Surgery Fellowship Program at the University of Utah. Dr Kraiss has twice received teaching awards from the University of Utah general surgery residents. In 1997 he received the prestigious Wylie Scholar in Academic Vascular Surgery Award from Vascular Cures.


Richard Powell, MD

Richard Powell, MD is Section Chief of Vascular Surgery at the Dartmouth-Hitchcock Medical Center in New Hampshire, where he joined the staff in 1997. He received his medical degree from Medical College of Wisconsin, Milwaukee in 1986 and was selected as the Wylie Scholar in Academic Vascular Surgery Award recipient in 1999. Dr. Powell is currently leading an international clinical trial to evaluate a new type of stent for patients with advanced peripheral artery disease (PAD). He is also working on two clinical trials involving gene and stem cell therapies to prevent limb amputation in patients with advanced peripheral artery disease or critical limb ischemia (CLI).


Paul M. Ridker, MD

Paul M. Ridker, MD is the Eugene Braunwald Professor of Medicine at The Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston. He also serves on the Board of External Experts for the National Heart Lung and Blood Institute. Dr. Ridker’s research focuses on inflammatory biomarkers and novel strategies for cardiovascular disease detection and prevention.

Dr. Ridker is best known for his work developing the inflammatory hypothesis of heart disease, the clinical application of C-reactive protein (hsCRP) testing to better evaluate cardiovascular risk, and the demonstration in the JUPITER trial that statin therapy is highly effective at reducing heart attack and stroke. He is the author of over 450 original reports, 170 reviews and book chapters, and five textbooks related to cardiovascular medicine. Dr. Ridker is a co-inventor on a series of patents filed by the Brigham and Women’s Hospital and Harvard Medical School that relate to the use of inflammatory biomarkers in cardiovascular disease.


Campbell Rogers, MD

Campbell Rogers, MD serves as the Chief Medical Officer of HeartFlow, Inc. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, Dr. Rogers was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women's Hospital. His research explored biological underpinnings of vascular responses to mechanical injury, and he served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, and is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases. Dr. Rogers was the recipient of research grant awards from the NIH and AHA. He received his A.B. from Harvard College and his M.D. from Harvard Medical School.


Barry Rubin, MD, PhD, FRCSC

Dr. Barry Rubin, MD PhD FRCSC is the Chair and Medical Director of the Peter Munk Cardiac Centre (PMCC) at University Health Network, Canada’s largest cardiovascular unit as well as Professor of Surgery at the University of Toronto. He was the 1998 Wylie Scholar. Dr. Rubin has been Chair and CEO of the Mount Sinai Hospital University Health Network Academic Medical Organization since 2003, having been unanimously re-elected to this position 3 times by his peers. This organization supports teaching, research, innovation, recruitment and retention of 750 physicians at University Health Network and Mount Sinai Hospital. Dr. Rubin’s basic science research laboratory has been continuously funded by the Canadian Institutes of Health Research (CIHR) for 16 years. He has been widely published in high impact journals. He implemented a system throughout PMCC to evaluate and fund innovative research projects. Since 2012, they have funded 37 research projects. According to UNH, Dr. Rubin is one of the world’s most gifted vascular surgeons.


Charles N. Serhan, PhD

Charles N. Serhan, PhD is Director of the Center for Experimental Therapeutics and Reperfusion Injury (CET&RI) at Brigham and Women's Hospital, and a Professor of Anesthesia at Harvard Medical School, affiliated with the Department of Biological Chemistry and Molecular Pharmacology. Dr. Serhan is working on cellular and molecular mechanisms that are involved in the control of local inflammatory processes.

Since inflammation plays a role in many organs and diseases, understanding this control is key to unlocking potential new treatments for diseases where chronic inflammation is thought to play a critical role. These include cardiovascular diseases, auto-immune diseases, arthritis, and Alzheimer's disease. The molecules that Dr. Serhan and colleagues are working on can serve as bio-templates for creating designer therapies to stimulate resolution of inflammation and disease.


Edith Tzeng, MD

Edith Tzeng, MD is Professor of Surgery and Chief of Vascular Surgery at the University of Pittsburgh. She is focused on the problems of blood vessels healing after injury, bypass, or angioplasty. She received her medical degree from the University of Chicago, The Pritzker School Of Medicine. In 2001 she was awarded Vascular Cures' Wylie Scholar in Academic Vascular Surgery research grant. Dr. Tzeng is also the Chief of Vascular Surgery at the Veterans’ Administration Medical Center in Pittsburgh, Pennsylvania.


Renu Virmani, MD

Renu Virmani, MD currently serves as President and Medical Director, CVPath, International Registry of Pathology in Gaithersburg, MD. She is recognized as one of the leaders in the search for diagnostic and treatment therapies for vulnerable plaque. Dr. Virmani is also Clinical Professor, Department of Pathology at Georgetown University, University of Maryland-Baltimore, Uniform University of Health Sciences and Vanderbilt University. She is responsible for multiple research grants in the field of pathology  most recently, a $1.3 million grant from the NIH for plaque progression, apoptosis, and inflammation. Dr. Virmani is an active lecturer and has authored over 300 publications in peer-reviewed journals in the field of atherosclerosis and vulnerable plaque, stents, and other cardiovascular diseases. She has received honorary awards that include the Joint Service Commendation Medal for Outstanding Meritorious Service as Chief of Cardiovascular Pathology, Armed Forces Institute of Pathology (1979-1981). Dr. Virmani received her medical degree from Lady Hardinge Medical College, Delhi University, in New Delhi, India.